Efficacy and Safety of MED-01 Probiotics on Vaginal Health: A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Nutrients · 2023
DOI: 10.3390/nu15020331 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, 2023. Verfasst von Sung-Ho Park und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hallym University Kangnam Sacred Heart Hospital, 665 Siheung-daero, Yeongdeungpo-gu, Seoul 07442, Republic of Korea. Hauptthemen laut MEDLINE: Vaginosis, Bacterial, Probiotics. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Ministry of SMEs and Startups(MSS, Korea), Ministry of SMEs and Startups (MSS, Korea).
Abstract (Originalsprache)
Bacterial vaginosis (BV) is the most common disease in women of childbearing age and is caused by the growth of abnormal microbiota in the vagina. Probiotic consumption can be an effective alternative treatment to preserve or improve vaginal health. In the present study, MED-01, a complex of five strains of probiotic candidates isolated from the vagina of Korean women, was used. This study was designed as a 12-week, randomized, multicenter, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of MED-01 on vaginal health. A total of 101 reproductive-aged women with a Nugent score of 4–6 took MED-01 (5.0 × 109 CFU) or a placebo once a day, and 76 participants completed the procedure. MED-01 significantly reduced the Nugent score compared with the placebo. Quantitative PCR analysis confirmed that Lactobacillus plantarum was significantly increased in the vagina, whereas harmful bacteria such as Mobiluncus spp., Gardnerella vaginalis, and Atopobium vaginae were suppressed after 12 weeks of MED-01 ingestion. No adverse events to the test food supplements were observed in the participants. These results confirmed that MED-01 can be used as a probiotic for treating BV, as it improves the vaginal microbiota.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hallym University Kangnam Sacred Heart Hospital, 665 Siheung-daero, Yeongdeungpo-gu, Seoul 07442, Republic of Korea.
- Soonchunhyang University Seoul Hospital, 59 Daesagwan-ro, Yongsan-gu, Seoul 04401, Republic of Korea.
- Mediogen, Co., Ltd., Biovalley 1-ro, Jecheon-si 27159, Chungcheongbuk-do, Republic of Korea.
- Department of Obstetrics and Gynecology, College of Medicine Chung-Ang University, Chung-Ang University Gwangmyeong Hospital, 501 Iljik-dong, Gwangmyeong-si 14353, Gyeonggi-do, Republic of Korea.
ORCID-Profile: Sung Taek Park, Yeoul Yun, YongGyeong Kim, Yulah Jeong, Chang-Ho Kang
Förderung
- the Ministry of SMEs and Startups(MSS, Korea)
- Ministry of SMEs and Startups (MSS, Korea)
Zitieren
APA
Park, S. H., Lee, E. S., Park, S. T., Jeong, S. Y., Yun, Y., Kim, Y., Jeong, Y., Kang, C. H., & Choi, H. J. (2023). Efficacy and Safety of MED-01 Probiotics on Vaginal Health: A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Nutrients. https://doi.org/10.3390/nu15020331
Vancouver
Park SH, Lee ES, Park ST, Jeong SY, Yun Y, Kim Y, et al. Efficacy and Safety of MED-01 Probiotics on Vaginal Health: A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Nutrients. 2023. doi:10.3390/nu15020331
BibTeX
@article{Park2023,
author = {Park, Sung-Ho and Lee, Eun Sil and Park, Sung Taek and Jeong, Soo Young and Yun, Yeoul and Kim, YongGyeong and Jeong, Yulah and Kang, Chang-Ho and Choi, Hyun Jin},
title = {Efficacy and Safety of MED-01 Probiotics on Vaginal Health: A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial},
journal = {Nutrients},
year = {2023},
doi = {10.3390/nu15020331}
}
EUVIMED